ADR | Chemotherapy regimens | P-Value* | |||||||
---|---|---|---|---|---|---|---|---|---|
FOLOFOX | FOLFIRI | Capecitabine + Cetuximab | Capecitabine | FOLOFOX + Irinotecan | 5-FU | Total | |||
Diarrhea | Grade 1 | 14 (35.9%) | 4 (28.6%) | 0 (0%) | 1 (100%) | 2 (100%) | 0 (0%) | 21 (37.5%) | 0.96 |
Grade 2 | 12 (30.8%) | 5 (35.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 17 (30.4%) | ||
Grade 3 | 7 (17.9%) | 3 (21.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 10 (17.9%) | ||
Grade 4 | 6 (15.4%) | 2 (14.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (14.3%) | ||
Nausea | Grade 1 | 33 (68.8%) | 7 (50%) | 1 (50%) | 2 (100%) | 2 (66.7%) | 0 (0%) | 45 (64.3%) | 0.32 |
Grade 2 | 14 (29.2%) | 7 (50%) | 1 (50%) | 0 (0%) | 1 (33.3%) | 1 (100%) | 24 (34.3%) | ||
Grade 3 | 1 (2.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.4%) | ||
Vomiting | Grade 1 | 17 (6.7%) | 5 (55.6%) | 1 (100%) | 2 (100%) | 1 (33.3%) | 1 (100%) | 27 (61.4%) | 0.91 |
Grade 2 | 7 (25%) | 3 (33.3%) | 0 (0%) | 0 (0%) | 2 (66.7%) | 0 (0%) | 12 (27.3%) | ||
Grade 3 | 3 (10.7%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (9.1%) | ||
Grade 4 | 1 (3.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.3%) | ||
Oral mucositis | Grade 1 | 24 (61.4%) | 11 (61.1%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 36 (46.2%) | |
Grade 2 | 19 (27.3%) | 4 (22.2%) | 0 (0%) | 2 (100%) | 1 (50%) | 1 (100%) | 27 (34.6%) | 0.59 | |
Grade 3 | 11 (9.1%) | 3 (16.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (17.9%) | ||
Grade 4 | 1 (2.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.3%) | ||
Peripheral neuropathy | Grade 1 | 89 (56%) | 16 (44.4%) | 0 (0%) | 2 (40%) | 4 (80%) | 0 (0%) | 111 (53.1%) | 0.39 |
Grade 2 | 69 (43.4%) | 20 (55.6%) | 3 (100%) | 2 (40%) | 1 (20%) | 1 (100%) | 96 (45.9%) | ||
Grade 3 | 1 (0.6%) | 0 (0%) | 0 (0%) | 1 (20%) | 0 (0%) | 0 (0%) | 2 (1%) | ||
Hair loss | Grade 1 | 53 (94.6%) | 19 (79.2%) | 2 (100%) | 5 (100%) | 1 (33.3%) | 0 (0%) | 80 (87.9%) | 0.03 |
Grade 2 | 3 (5.4%) | 5 (20.8%) | 0 (0%) | 0 (0%) | 2 (66.7%) | 1 (100%) | 11 (12.1%) |